Leading Health and Life Sciences in Nova Scotia

Electric Puppets helps IWK Children’s Hospital and Nova Scotian libraries support quarantined folks to continue to access critical services and technology

Read original here

The COVID-19 pandemic has placed members of our community off work and out of school as they are self-isolate at home. Electric Puppets is working with the IWK Children’s hospital to find ways to increase access to services for Nova Scotians while at home, including medical assessments, ability to participate in research, and access to technology that can be used for education and opportunities to explore virtually. Over the coming weeks and months, we will be working to specifically address vision testing and assessment for existing and new patients at the IWK throughout the province and will be working on getting equipment to them so they can continue to be assessed while at home. As the program expands to wider patient groups, Electric Puppets is exploring ways to leverage community resources, and it’s hoped that an emerging relationship with the Nova Scotia Provincial Library could lead to community support from public libraries to provide high speed internet service, manage equipment loans, and assist community members as they access services.

“In light of the COVID-19 pandemic, the IWK Eye Clinic will be developing a remote vision assessment protocol to ensure on-going care and interaction with patients and families. We are interested to include Electric Puppets in this endeavor and modify the Evrisia project in order to achieve this goal.”

Appili Therapeutics Announces Closing of Public Offering of $15,525,000 and Concurrent Private Placement of $1,440,000

Read more here

Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”) announced the closing of its previously announced public offering (the “Public Offering”) of units (the “Units”). The Public Offering was made pursuant to an agency agreement entered into with a syndicate of agents led by Bloom Burton Securities Inc. (the “Lead Agent”) and including Mackie Research Capital Corporation, Industrial Alliance Securities Inc., Haywood Securities Inc., and Richardson GMP Limited (collectively with the Lead Agent, the “Agents”) and the Company.

Pursuant to the Public Offering, the Company issued a total of 12,937,500 Units at a price of $1.20 per Unit for aggregate gross proceeds of $15,525,000, which includes the exercise in full by the Agents of their over-allotment option to purchase 1,687,500 additional Units for additional gross proceeds of $2,025,000. Each Unit is comprised of one Class A common share of the Company (a “Common Share”) and one-half of one Common Share purchase warrant of the Company (each whole Common Share purchase warrant, a “Warrant”). Each Warrant entitles the holder thereof to acquire one Common Share (a “Warrant Share”) at an exercise price of $1.50 per Warrant Share until June 10, 2023.

“Appili has entered the global effort to solve the COVID-19 pandemic, and our team, along with our partners, including Fujifilm Toyama Chemical and Sinai Health, are working diligently to advance this randomized controlled trial as quickly and as thoroughly as possible,” said Dr. Armand Balboni, Chief Executive Officer, Appili Therapeutics. “Appili was built to solve infectious disease problems, and we believe that favipiravir will be an important part of the arsenal that ultimately addresses this coronavirus pandemic. With the continued support from the investment community, the results of this fundraise bolsters our capacity to push forward our Phase 2 program, which is designed to address a critical unmet need for the most vulnerable COVID-19 patients.”

The net proceeds of the Public Offering will be used primarily towards funding planned research and development activities for the clinical trial sponsored by the Company evaluating FUJIFILM Toyama Chemical Inc.’s (“FFTC”) drug favipiravir in long-term care facilities as a potential preventative measure against COVID-19.

Owner of Tranquility Online offers a virtual helping hand

Read original here

Health services are currently preoccupied with COVID-19. But if your mental health is suffering, where can you go? Joel Muise, owner of Tranquility, pivoted his online therapy platform counselling app to help support those struggling with the mental health effects of the pandemic. He kept true to his core mission and found an even larger customer base; one that needed his services during these challenging times.

“As soon as it became apparent that COVID-19 was going to turn into a global pandemic, we quickly realized that because we had a virtual mental health platform we should be part of the solution.” – Joel Muise, owner of Tranquility.

When the pandemic struck, we all had more questions than the world had answers. This gap has since increased in many ways, and with it, the amount of anxiety felt by all Canadians. Combine that with the reality that we’re largely forced to be alone, without our friends and family by our side, and you have an unmanageable amount of stress. That’s why Joel Muise, owner of Nova Scotia’s online Cognitive Behavioural Therapy service for stress and anxiety, Tranquility, decided to change his business model to help Canadians cope right now.

When social distancing protocols were announced, he knew Tranquility could help because the platform provides virtual help for mental health. Muise says, “We quickly made some changes to our platform to address what people may be going through right now (e.g., health related anxiety, social anxiety, financial distress) and then started to reach out to organizations to see how we can support our healthcare and frontline workers, free of charge.” He then marketed his new offering so people could find help during this challenging time.

Outcast Foods & Greenhouse Partner for a Zero Waste Future

Read original here

Outcast Foods will upcycle pulp byproduct from Greenhouse’s juice processing operation into isolated dried fruit and vegetable powders for innovative, sustainable new products. 

Two Canadian wellness companies have embarked on early stages of a partnership to ultimately eliminate millions of pounds of surplus food byproducts. “The process of cold-pressed juicing creates nutrient dense, high-value juice but results in a large amount of leftover pulp. Typically, this pulp ends up in landfills with a small percentage used in agricultural feed,” said Outcast Foods CEO Dr. Darren Burke. “However, our unique sustainable food technology can be used to recover high value nutrients, polyphenols and fiber remaining in the pulp and make it a valuable raw material for innovative and sustainable food products.”

Outcast Foods uses a state-of-the art three step process to dry fruits and vegetables, immediately locking in the nutrients and extending shelf life to 3 years. The company mission is to create sustainable nutrition for health and the planet by altering our broken food system. “With more uncertainty in our food supply chain now than ever, it’s critical to find ways to reduce food waste; upcycling Greenhouse’s pulp will provide high quality North American fruit & vegetable powders that will end up in delicious and sustainable new products,” said TJ Galiardi, co-founder of Outcast Foods.

T4G Acquired by National Firm MNP

Read original here

T4G has been purchased for an undisclosed price by national accounting and consulting firm MNP, which wants access to the target company’s expertise in data analytics and machine learning.

Though headquartered in Toronto, T4G is one of the pillars of the Atlantic Canadian tech community with offices in Halifax and Saint John. It was the driving force behind the Big Data Congress, which was a major event in the startup calendar for several years.

Based in Calgary, MNP is one of Canada’s largest national accounting, tax and business consulting firms. It said Monday it is retaining virtually all of T4G’s 100 employees and plans to grow the business, including the teams in Atlantic Canada.

“We’ve been talking to this company for a while,” said T4G Co-Founder and President Geoff Flood in an interview. “We’ve had a lot of suitors over the years and it never felt quite right until about now.”

Health Canada Clears Appili Therapeutics’ Phase 2 Clinical Trial Evaluating Favipiravir as a Prophylactic Agent Against COVID-19 Outbreaks

Read original here

Appili Therapeutics Inc., a biopharmaceutical company focused on anti-infective drug development, today announced that Health Canada provided regulatory clearance for Appili’s Phase 2 study evaluating FUJIFILM Toyama Chemical’s (FFTC) favipiravir as a preventative measure against COVID-19 outbreaks. Dr. Allison McGeer, senior clinician scientist at Sinai Health’s Lunenfeld-Tanenbaum Research Institute in Toronto, Ontario is the study’s primary investigator. Appili expects trial recruitment to begin imminently. Researchers will enroll approximately 760 subjects, both residents and staff, at 16 long-term care homes (LTCHs) in Ontario. The National Institute on Ageing has estimated that as of May 6, 2020, 82 percent of deaths related to COVID-19 in Canada were associated with long-term care facilities.[i]

“Given the severity of COVID-19 amongst the elderly, and the evidence of ongoing transmission with severe outcomes in LTCHs, it is critical to develop interventions that minimize the spread of disease in this setting. As vaccines and treatment for COVID-19 remain unavailable, we must explore all possible solutions,” said Dr. McGeer. “We look forward to working with Appili on this study, as the pandemic continues to present devastating consequences for LTCH residents and their families.”